Skip to content

Study · In vitro (cells) · 1990

3 results

Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system.

Grillon C, Rieger K, Bakala J, Schott D, Morgat JL, Hannappel E, Voelter W, Lenfant M

FEBS letters1 Nov 1990Cited by 93 (Europe PMC)

PMID2253778 (opens in a new tab)DOI10.1016/0014-5793(90)81322-f (opens in a new tab)PepBankPUB-02253778
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In intact or lysed bone marrow cells, incubation with labelled thymosin beta‑4 led to formation of labelled AcSDKP, and the tetrapeptide was not degraded under these conditions.

    In plain wordsIn bone marrow cells, thymosin beta‑4 was cleaved to the small peptide AcSDKP, which was not broken down in the test.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableFormation of AcSDKP from labelled Tβ4 in bone marrow cells
    Study

    n: not reported in source

    bone marrow cells (BMC)
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Incubation of [3H]T beta 4 with either intact or lysed BMC led to the formation of [3H]AcSDKP whereas the labelled tetrapeptide was not degraded under these conditions.
    1 context sentence
    Summary · context
    It is shown that AcSDKP a new regulator of the hematopoietic system can be generated from thymosin beta 4 by a one-step enzymatic cleavage in vitro and in vivo.
  2. 02LabIn vitro (cell-free)Mechanism

    In a model degradation of thymosin beta‑4 with bacterial enzymes, the pattern suggested that a mammalian endoproteinase Asp-N may form AcSDKP by cutting the 4Pro-5 Asp bond of thymosin beta‑4.

    In plain wordsIn lab tests with bacterial enzymes, results suggested a mammalian enzyme could cut thymosin beta‑4 to make AcSDKP.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableCleavage of Tβ4 by enzymes at the 4Pro-5 Asp bond
    Study

    n: not reported in source

    bacterial enzymes (model degradation of Tβ4)
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Model enzymatic degradation of T beta 4 carried out with bacterial enzymes suggests that a mammalian endoproteinase Asp-N might be involved in the formation of AcSDKP through the specific cleavage of the 4Pro-5 Asp peptide bond of T beta 4.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 03LabEndogenous levelIn vitro (cells)Other

    Both AcSDKP and the body's own thymosin beta‑4 were detected in bone marrow cells.

    In plain wordsIn bone marrow cells, the body's own thymosin beta‑4 and AcSDKP were both found.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableDetection of Tβ4 and AcSDKP in bone marrow cells
    Study

    n: not reported in source

    bone marrow cells (BMC)
    Outcome group
    Gene expression · Immune and inflammation

    Source sentences

    Summary
    AcSDKP and T beta 4 were both detected in bone marrow cells (BMC).
    1 context sentence
    Summary · context
    It is shown that AcSDKP a new regulator of the hematopoietic system can be generated from thymosin beta 4 by a one-step enzymatic cleavage in vitro and in vivo.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.